Cellular Biology With Dr. Marjan Assefi

Scientists are trying to reach inside cells where they can be difficult to get to. Through a reasonable methodology of inside-created advances and outer joint efforts, we are gaining ground in tending to the difficulties of intracellular focusing of treatments.

We center around the expected utilization of mRNA to create treatments straightforwardly in the cell, transforming the cell into ‘natural manufacturing plants’ that produce the remedial proteins, antigens, or potentially antibodies to treat ailing organs and tissues.

RNA therapeutics offer the potential to tweak cell pathways in manners not already conceivable explicitly. Be that as it may, we really want to get the RNA atoms into the cytosol of the cell.

We are researching lipid nanoparticles (LNPs) as a promising vehicle for the intracellular conveyance of mRNA to create protein therapeutics in cells. LNPs have a compelling history of conveying nucleic acids and they are by a long shot the most exceptional conveyance approach for mRNA conveyance. Accordingly, they are the normal decision as a conveyance vehicle in this exploration front.

We have shown that mRNA typified in LNPs can convey mRNA inside cells and start cell protein creation after intravenous, subcutaneous, and lung organization. We are presently zeroing in on our examination on improving the viability and security profile of this medication conveyance framework.